tradingkey.logo

Evolus Inc

EOLS
4.500USD
+0.090+2.04%
終値 02/06, 16:00ET15分遅れの株価
291.45M時価総額
損失額直近12ヶ月PER

Evolus Inc

4.500
+0.090+2.04%

詳細情報 Evolus Inc 企業名

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Incの企業情報

企業コードEOLS
会社名Evolus Inc
上場日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)
従業員数332
証券種類Ordinary Share
決算期末Feb 08
本社所在地520 Newport Center Dr Ste 1200
都市NEWPORT BEACH
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92660-7022
電話番号19492844555
ウェブサイトhttps://www.evolus.com/
企業コードEOLS
上場日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)

Evolus Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+23000.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
+104603.00%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+30000.00%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-5900.00%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-127905.00%

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
他の
62.24%
株主統計
株主統計
比率
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
他の
62.24%
種類
株主統計
比率
Hedge Fund
39.18%
Investment Advisor
21.75%
Investment Advisor/Hedge Fund
15.75%
Individual Investor
10.05%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.43%
Bank and Trust
0.25%
他の
2.85%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Nantahala Capital Management, LLC
5.73M
8.84%
+1.53M
+36.42%
Sep 30, 2025
Tang Capital Management, LLC
5.49M
8.47%
+490.90K
+9.82%
Sep 30, 2025
Lynch (Timothy Patrick)
5.13M
7.92%
+1.04M
+25.38%
Sep 30, 2025
Caligan Partners, LP
4.14M
6.39%
+796.97K
+23.85%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
6.15%
+339.54K
+9.30%
Sep 30, 2025
The Vanguard Group, Inc.
3.42M
5.27%
+110.69K
+3.35%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
2.63M
4.06%
+195.12K
+8.01%
Sep 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.86M
2.87%
+375.58K
+25.32%
Sep 30, 2025
Stonepine Capital Management, LLC
1.54M
2.37%
+619.89K
+67.64%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
詳細を見る
State Street SPDR S&P Pharmaceuticals ETF
比率0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率0.93%
iShares U.S. Pharmaceuticals ETF
比率0.15%
iShares Micro-Cap ETF
比率0.07%
ProShares Ultra Nasdaq Biotechnology
比率0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.06%
Invesco Nasdaq Biotechnology ETF
比率0.04%
ProShares Hedge Replication ETF
比率0.02%
iShares Russell 2000 Growth ETF
比率0.02%
Schwab U.S. Small-Cap ETF
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI